Circadian owns Vegenics
Thursday, 14 August, 2008
Circadian Technologies [ASX: CIR] is now the sole owner of Vegenics, having completed the acquisition of the company today.
Circadian announced the planned acquisition on July 15. Prior to that point, the company held a 66 per cent stake in Vegenics.
Among the intellectual property Circadian has assumed control of are the proteins VEGF-C and VEGF-D, which if blocked may inhibit rumour growth and prevent the spread of new cancer cells.
Circadian has also acquired Vegenics' product pipeline, including drug candidates based on the VEGF-C and VEGF-D protein IPs.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
